{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:45:50Z","timestamp":1790999150160,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T00:00:00Z","timestamp":1601596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Axon Pharma Laboratory"},{"DOI":"10.13039\/501100006255","name":"Universidad de Concepci\u00f3n","doi-asserted-by":"publisher","award":["UR 2623256401"],"award-info":[{"award-number":["UR 2623256401"]}],"id":[{"id":"10.13039\/501100006255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00213-020-05617-6","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T21:02:48Z","timestamp":1601672568000},"page":"3357-3367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial"],"prefix":"10.1007","volume":"237","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8903-6170","authenticated-orcid":false,"given":"Benjam\u00edn","family":"Vicente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Saldivia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na\u00edn","family":"Hormazabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bustos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rub\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,2]]},"reference":[{"key":"5617_CR1","first-page":"74","volume":"1","author":"Y Aleksandrovsky","year":"2010","unstructured":"Aleksandrovsky Y, Krasnov V, Neznanov N, Romasenko L (2010) Efficacy of etifoxine versus phenazepam in the treatment of patients with adjustment disorders (open randomized controlled trial). Russ Psychiatr J 1:74\u201378","journal-title":"Russ Psychiatr J"},{"key":"5617_CR2","unstructured":"Alfa Beta (2019) Manual Farmacoterape\u00fatico On Line. STRESAM. http:\/\/www.alfabeta.net\/medicamento\/stresam.vademecum"},{"key":"5617_CR3","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.4067\/S0034-98872009001100008","volume":"137","author":"ME Alvarado","year":"2009","unstructured":"Alvarado ME, Garmendia ML, Acu\u00f1a G, Santis R, Arteaga O (2009) Validez y confiabilidad de la versi\u00f3n chilena del alcohol use disorders identification test (AUDIT). Rev Med Chil 137:1463\u20131468. https:\/\/doi.org\/10.4067\/S0034-98872009001100008","journal-title":"Rev Med Chil"},{"key":"5617_CR4","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1177\/0004867418799453","volume":"52","author":"G Andrews","year":"2018","unstructured":"Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, Rapee R, Wilkins G (2018) Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry 52:1109\u20131172. https:\/\/doi.org\/10.1177\/0004867418799453","journal-title":"Aust N Z J Psychiatry"},{"key":"5617_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/BF00789001","volume":"27","author":"R Araya","year":"1992","unstructured":"Araya R, Wynn R, Lewis G (1992) Comparison of two self administered psychiatric questionnaires (GHQ-12 and SRQ-20) in primary care in Chile. Soc Psychiatry Psychiatr Epidemiol 27:168\u2013173. https:\/\/doi.org\/10.1007\/BF00789001","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"5617_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2165\/00003495-199448010-00004","volume":"48","author":"H Ashton","year":"1994","unstructured":"Ashton H (1994) Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 48:25\u201324","journal-title":"Drugs"},{"key":"5617_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/0269881114525674","volume":"28","author":"DS Baldwin","year":"2014","unstructured":"Baldwin DS, Anderson IM, Nutt DJ, Allgulander C, Bandelow B, den Boer JA, Christmas DM, Davies S, Fineberg N, Lidbetter N, Malizia A, McCrone P, Nabarro D, O\u2019Neill C, Scott J, van der Wee N, Wittchen HU (2014) Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol 28:403\u2013439. https:\/\/doi.org\/10.1177\/0269881114525674","journal-title":"J Psychopharmacol"},{"key":"5617_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","volume":"30","author":"B Bandelow","year":"2015","unstructured":"Bandelow B, Reitt M, R\u00f6ver C, Michaelis S, G\u00f6rlich Y, Wedekind D (2015) Efficacy of treatments for anxiety disorders. Int Clin Psychopharmacol 30:183\u2013192. https:\/\/doi.org\/10.1097\/YIC.0000000000000078","journal-title":"Int Clin Psychopharmacol"},{"key":"5617_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4067\/S0717-92272012000200002","volume":"50","author":"V Boehme","year":"2012","unstructured":"Boehme V, Dur\u00e1n E (2012) Experiencia clinica con el antipsic\u00f3tico clozapina en ni\u00f1os y adolescentes menores de 18 a\u00f1os en Chile. Rev Chil Neuropsiquiatr 50:85\u201399","journal-title":"Rev Chil Neuropsiquiatr"},{"key":"5617_CR10","unstructured":"Bozzo G (2010) Estudio cualitativo del uso de ansiol\u00edticos en pacientes de farmacias comunitarias Salcobrand de la ciudad de Valdivia. Universidad Austral de Chile"},{"key":"5617_CR11","unstructured":"Busto M (1991) BDZ: La tranquila adicci\u00f3n de Santiago. Corporaci\u00f3n de Salud y Pol\u00edticas P\u00fablicas, Santiago de Chile"},{"key":"5617_CR12","first-page":"107","volume":"46","author":"A Cavieres","year":"2008","unstructured":"Cavieres A (2008) Hiperprolactinaemia and sexual disfunction in first psychotic episode treated with risperidone. Rev Chil Neuropsiquiatr 46:107\u2013114","journal-title":"Rev Chil Neuropsiquiatr"},{"key":"5617_CR13","doi-asserted-by":"publisher","unstructured":"Chessick CA, Allen MH, Thase ME, Batista Miralha da Cunha AABC, Kapczinski F, Silva de Lima M, dos Santos Souza JJSS, Cochrane Common Mental Disorders Group (2006) Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev:CD006115. https:\/\/doi.org\/10.1002\/14651858.CD006115","DOI":"10.1002\/14651858.CD006115"},{"key":"5617_CR14","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3344\/kjp.2015.28.1.4","volume":"28","author":"YM Choi","year":"2015","unstructured":"Choi YM, Kim KH (2015) Etifoxine for pain patients with anxiety. Korean J Pain 28:4\u201310. https:\/\/doi.org\/10.3344\/kjp.2015.28.1.4","journal-title":"Korean J Pain"},{"key":"5617_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1046\/j.0306-5251.2001.01424.x-i1","volume":"52","author":"Committee for Propietary Medicinal Products","year":"2001","unstructured":"Committee for Propietary Medicinal Products (2001) Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol 52:224\u2013228. https:\/\/doi.org\/10.1046\/j.0306-5251.2001.01424.x-i1","journal-title":"Br J Clin Pharmacol"},{"key":"5617_CR16","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/fcp.12169","volume":"30","author":"J Cottin","year":"2016","unstructured":"Cottin J, Gouraud A, Jean-Pastor MJ, Dautriche AD, Boulay C, Geniaux H, Auffret M, Bernard N, Descotes J, Vial T (2016) Safety profile of etifoxine: a French pharmacovigilance survey. Fundam Clin Pharmacol 30:147\u2013152. https:\/\/doi.org\/10.1111\/fcp.12169","journal-title":"Fundam Clin Pharmacol"},{"key":"5617_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02316856","volume":"105","author":"HV Curran","year":"1991","unstructured":"Curran HV (1991) Psychopharmacology benzodiazepines, memory and mood: a review. Psychopharmacology 105:1\u20138","journal-title":"Psychopharmacology"},{"key":"5617_CR18","first-page":"32","volume":"26","author":"A Danhier","year":"1988","unstructured":"Danhier A, Brieba J, Villegas G et al (1988) Estudio sobre la utilizaci\u00f3n de psicof\u00e1rmacos en la ciudad de Concepci\u00f3. Rev Chil Neuropsiquiatr 26:32\u201338","journal-title":"Rev Chil Neuropsiquiatr"},{"key":"5617_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.rchipe.2015.04.027","volume":"86","author":"LV De La Maza","year":"2015","unstructured":"De La Maza LV, Fern\u00e1ndez CM, Concha RL et al (2015) Impact of an educational program for parents of children with cancer on the increased knowledge of their children\u2019s disease and the decrease in anxiety [Impacto de un programa educativo a los padres de ni\u00f1os con c\u00e1ncer en el aumento del conocimiento de la. Rev Chil Pediatr 86:351\u2013356. https:\/\/doi.org\/10.1016\/j.rchipe.2015.04.027","journal-title":"Rev Chil Pediatr"},{"key":"5617_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1600-0447.1998.tb05974.x","volume":"98","author":"M Ferreri","year":"1998","unstructured":"Ferreri M, Hantouche EG (1998) Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatr Scand 98:102\u2013108. https:\/\/doi.org\/10.1111\/j.1600-0447.1998.tb05974.x","journal-title":"Acta Psychiatr Scand"},{"key":"5617_CR21","first-page":"286","volume":"33","author":"R Fritsch","year":"2005","unstructured":"Fritsch R, Rojas G, Gaete J et al (2005) Consumo de benzodiazepinas en la poblaci\u00f3n general del Gran Santiago de Chile. Actas Esp Psiquiatr 33:286\u2013291","journal-title":"Actas Esp Psiquiatr"},{"key":"5617_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.4067\/S0034-98872003000500009","volume":"131","author":"T Galleguillos","year":"2003","unstructured":"Galleguillos T, Risco L, Garay JL et al (2003) Tendencia del uso de benzodiazepinas en una muestra de consultantes en atenci\u00f3n primaria. Rev Med Chil 131:535\u2013540. https:\/\/doi.org\/10.4067\/S0034-98872003000500009","journal-title":"Rev Med Chil"},{"key":"5617_CR23","volume-title":"Early Clinical Drug Evaluation (ECDEU). Assessment manual","author":"W Guy","year":"1976","unstructured":"Guy W (1976) Early Clinical Drug Evaluation (ECDEU). Assessment manual. National Institute Mental Health, Rockville"},{"key":"5617_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50\u201355. https:\/\/doi.org\/10.1111\/j.2044-8341.1959.tb00467.x","journal-title":"Br J Med Psychol"},{"key":"5617_CR25","unstructured":"Instituto de Salud P\u00fablica de Chile (2010) Acta No 3 \/ 10"},{"key":"5617_CR26","unstructured":"Instituto de Salud P\u00fablica de Chile (2020) Registro F-22632\/16. http:\/\/registrosanitario.ispch.gob.cl\/Ficha.aspx?RegistroISP=F-22632\/16. Accessed 9 Jan 2020"},{"key":"5617_CR27","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1017\/S003329170800384X","volume":"38","author":"K Kendrler","year":"2008","unstructured":"Kendrler K, Gardner C, Lichtenstein P (2008) A developmental twin study of symptoms of anxiety and depression: evidence for genetic innovation and attenuation. Psychol Med 38:1567\u20131575. https:\/\/doi.org\/10.1017\/S003329170800384X","journal-title":"Psychol Med"},{"key":"5617_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.eurpsy.2008.05.004","volume":"23","author":"DZ Knijnik","year":"2008","unstructured":"Knijnik DZ, Blanco C, Salum GA, Moraes CU, Mombach C, Almeida E, Pereira M, Strapasson A, Manfro GG, Eizirik CL (2008) A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. Eur Psychiatry 23:567\u2013574. https:\/\/doi.org\/10.1016\/j.eurpsy.2008.05.004","journal-title":"Eur Psychiatry"},{"key":"5617_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7764\/psykhe.21.2.550","volume":"21","author":"M Krebs","year":"2012","unstructured":"Krebs M, Mar\u00eda Gonz\u00e1lez L, Rivera A, Herrera Francisca Melis P (2012) Adherencia a Psicoterapia en Pacientes con Trastornos de Ansiedad adherence to psychotherapy in patients with anxiety disorders. Psykhe 21:133\u2013147. https:\/\/doi.org\/10.7764\/psykhe.21.2.550","journal-title":"Psykhe"},{"key":"5617_CR30","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","volume":"106","author":"M Lader","year":"2011","unstructured":"Lader M (2011) Benzodiazepines revisited-will we ever learn? Addiction 106:2086\u20132109. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03563.x","journal-title":"Addiction"},{"key":"5617_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","volume":"76","author":"O Lingj\u00e6rde","year":"1987","unstructured":"Lingj\u00e6rde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76:1\u2013100","journal-title":"Acta Psychiatr Scand"},{"key":"5617_CR32","first-page":"480","volume":"118","author":"A Lobo","year":"2003","unstructured":"Lobo A, Chamorro L, Luque A et al (2003) Validaci\u00f3n de las versiones en espa\u00f1ol de la Montgomery-Asberg Depression Rating Scale y la Hamilton Anxiety Rating Scale para la evaluaci\u00f3n de la depresi\u00f3n y de la ansiedad. Med Clin (Barc) 118:480\u2013520","journal-title":"Med Clin (Barc)"},{"key":"5617_CR33","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.psc.2009.05.004.The","volume":"32","author":"E Martin","year":"2009","unstructured":"Martin E, Ressler K, Binder E, Nemeroff C (2009) The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am 32:549\u2013575. https:\/\/doi.org\/10.1016\/j.psc.2009.05.004.The","journal-title":"Psychiatr Clin North Am"},{"key":"5617_CR34","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1590\/S0004-282X2000000600008","volume":"58","author":"A Martins Valenca","year":"2000","unstructured":"Martins Valenca A, Egidio Nardi A, Nascimiento I et al (2000) Double-blind clonazepam vs placebo in panic disorder treatment. Arq Neuropsiquiatr 58:1025\u20131029","journal-title":"Arq Neuropsiquiatr"},{"key":"5617_CR35","first-page":"1050","volume":"27","author":"D Mennecier","year":"2003","unstructured":"Mennecier D, Rimlinger H, Gidenne S et al (2003) Atteinte h\u00e9patique aigu\u00eb secondaire \u00e0 la prise de chlorhydrate d\u2019\u00e9tifoxine. Gastroenterol Clin Biol 27:1050\u20131051","journal-title":"Gastroenterol Clin Biol"},{"key":"5617_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1046\/j.1472-8206.2001.00025.x","volume":"15","author":"J Micallef","year":"2001","unstructured":"Micallef J, Soubrouillard C, Guet F, le Guern ME, Alquier C, Bruguerolle B, Blin O (2001) A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects. Fundam Clin Pharmacol 15:209\u2013216. https:\/\/doi.org\/10.1046\/j.1472-8206.2001.00025.x","journal-title":"Fundam Clin Pharmacol"},{"key":"5617_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-018-5152-9","volume":"236","author":"AL Milton","year":"2019","unstructured":"Milton AL, Holmes A (2019) Editorial: the psychopharmacology of extinction\u2014from theory to therapy. Psychopharmacology 236:1\u20136. https:\/\/doi.org\/10.1007\/s00213-018-5152-9","journal-title":"Psychopharmacology"},{"key":"5617_CR38","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/j.clinre.2012.04.002","volume":"36","author":"C Moch","year":"2012","unstructured":"Moch C, Rocher F, Lain\u00e9 P, Lacotte J, Biour M, Gouraud A, Bernard N, Descotes J, Vial T (2012) Etifoxine-induced acute hepatitis: a case series. Clin Res Hepatol Gastroenterol 36:e85\u2013e88. https:\/\/doi.org\/10.1016\/j.clinre.2012.04.002","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"5617_CR39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/hup.757","volume":"21","author":"N Nguyen","year":"2006","unstructured":"Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, le Guern ME, Micallef J, Blin O (2006) Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disroders with anxiety: a double-blind controlled study in general practice. Hum Psychopharmacol 21:139\u2013149. https:\/\/doi.org\/10.1002\/hup.757","journal-title":"Hum Psychopharmacol"},{"key":"5617_CR40","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.4067\/S0034-98872012001100009","volume":"140","author":"J Nogales-Gaete","year":"2012","unstructured":"Nogales-Gaete J, Aracena R, D\u00edaz V, Zitko P, Eloiza C, Cepeda-Zumaeta S, Agurto P, Gonz\u00e1lez C (2012) Evaluaci\u00f3n neuropsicol\u00f3gica en 129 pacientes chilenos con esclerosis m\u00faltiple recurrente remitente previo a inicio de f\u00e1rmacos inmunomoduladores. Rev Med Chil 140:1437\u20131444. https:\/\/doi.org\/10.4067\/S0034-98872012001100009","journal-title":"Rev Med Chil"},{"key":"5617_CR41","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2147\/NDT.S200568","volume":"15","author":"P Nuss","year":"2019","unstructured":"Nuss P, Ferreri F, Bourin M (2019) An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. Neuropsychiatr Dis Treat 15:1781\u20131795. https:\/\/doi.org\/10.2147\/NDT.S200568","journal-title":"Neuropsychiatr Dis Treat"},{"key":"5617_CR42","first-page":"53","volume":"3","author":"C Ojeda","year":"2007","unstructured":"Ojeda C (2007) An\u00e1lisis evolucionario de la angustia. Rev Gac Psiquiatr Univ 3:53\u201357","journal-title":"Rev Gac Psiquiatr Univ"},{"key":"5617_CR43","doi-asserted-by":"publisher","first-page":"132","DOI":"10.4067\/S0717-92272009000200005","volume":"47","author":"M Olivera","year":"2009","unstructured":"Olivera M (2009) Dependencia a benzodiazepinas en un centro de atenci\u00f3n primaria de salud: Magnitud del problema y orientaciones para el manejo integral. Rev Chil Neuropsiquiatr 47:132\u2013137. https:\/\/doi.org\/10.4067\/S0717-92272009000200005","journal-title":"Rev Chil Neuropsiquiatr"},{"key":"5617_CR44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.31887\/DCNS.2011.13.4\/cotte","volume":"13","author":"C Otte","year":"2011","unstructured":"Otte C (2011) Cognitive behavioral therapy in anxiety disorders: current state of the evidence. Dialogues Clin Neurosci 13:413\u2013421","journal-title":"Dialogues Clin Neurosci"},{"key":"5617_CR45","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2019","unstructured":"R Core Team (2019) R: A language and environment for statistical computing. Austria, Vienna"},{"key":"5617_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archpsyc.1981.01780290015001","volume":"38","author":"LN Robins","year":"1981","unstructured":"Robins LN, Helzer J, Croughan J, Ratcliff KS (1981) National Institute of Mental Health diagnostic interview schedule. Its history, characteristics, and validity. Arch Gen Psychiatry 38:381\u2013389. https:\/\/doi.org\/10.1001\/archpsyc.1981.01780290015001","journal-title":"Arch Gen Psychiatry"},{"key":"5617_CR47","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/archpsyc.1988.01800360017003","volume":"45","author":"L Robins","year":"1988","unstructured":"Robins L, Wing J, Ulrich H et al (1988) The Composite International Diagnostic Interview. Arch Gen Psychiatry 45:1069\u20131077","journal-title":"Arch Gen Psychiatry"},{"key":"5617_CR48","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1017\/S0033291710000176","volume":"40","author":"CD Sherbourne","year":"2010","unstructured":"Sherbourne CD, Sullivan G, Craske MG, Roy-Byrne P, Golinelli D, Rose RD, Chavira DA, Bystritsky A, Stein MB (2010) Functioning and disability levels in primary care out-patients with one or more anxiety disorders. Psychol Med 40:2059\u20132068. https:\/\/doi.org\/10.1017\/S0033291710000176","journal-title":"Psychol Med"},{"key":"5617_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12325-015-0176-6","volume":"32","author":"DJ Stein","year":"2015","unstructured":"Stein DJ (2015) Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv Ther 32:57\u201368. https:\/\/doi.org\/10.1007\/s12325-015-0176-6","journal-title":"Adv Ther"},{"key":"5617_CR50","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1080\/15622975.2018.1492736","volume":"19","author":"DJ Stein","year":"2018","unstructured":"Stein DJ (2018) Pharmacotherapy of adjustment disorder: a review. World J Biol Psychiatry 19:S46\u2013S52. https:\/\/doi.org\/10.1080\/15622975.2018.1492736","journal-title":"World J Biol Psychiatry"},{"key":"5617_CR51","first-page":"148","volume-title":"Introducci\u00f3n a la psicopatolog\u00eda y la psiquiatr\u00eda","author":"J Vallejo","year":"2015","unstructured":"Vallejo J, Bulbena A (2015) Trastornos de Angustia. In: Vallejo J, Bulbena A, Blanch J (eds) Introducci\u00f3n a la psicopatolog\u00eda y la psiquiatr\u00eda. Elsevier-Masson, Barcelona, pp 148\u2013163"},{"key":"5617_CR52","first-page":"151","volume":"44","author":"J Woods","year":"1992","unstructured":"Woods J, Katz J, Winger G (1992) Benzodiazepines : use, abuse and consequences. Pharmacol Rev 44:151\u2013347","journal-title":"Pharmacol Rev"},{"key":"5617_CR53","first-page":"9","volume":"47","author":"T Yates","year":"2009","unstructured":"Yates T, Catril P (2009) Tendencias en la utilizaci\u00f3n de benzodiazepinas en farmacia privada. Rev Chil Neuropsiquiatr 47:9\u201315","journal-title":"Rev Chil Neuropsiquiatr"},{"key":"5617_CR54","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1007\/s00213-018-5047-9","volume":"235","author":"T Zandonai","year":"2018","unstructured":"Zandonai T, Lugoboni F, Zamboni L (2018) A risk for athletes: when the desire to sleep becomes a nightmare. A brief case report on benzodiazepine addiction. Psychopharmacology 235:3359\u20133360. https:\/\/doi.org\/10.1007\/s00213-018-5047-9","journal-title":"Psychopharmacology"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-020-05617-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-020-05617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T23:28:39Z","timestamp":1633130919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-020-05617-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,2]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["5617"],"URL":"https:\/\/doi.org\/10.1007\/s00213-020-05617-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,2]]},"assertion":[{"value":"3 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}